Previous 10 | Next 10 |
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underway Company reschedules conference call and webcast to Wednesday, May 18 at 8:00 AM EDT BOSTON and JERUSALEM, May 12, 2...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . A Recession ...
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May 05, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd ....
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd . (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report business and financial results for the three months ended March 31, 2022 on Thursday,...
The following slide deck was published by Entera Bio Ltd. in conjunction with this event. For further details see: Entera Bio (ENTX) Investor Presentation - Slideshow
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd . (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company will participate at the Maxim Virtual Growth Conference. Maxim Virtual Growth...
Entera Bio Ltd. (ENTX) Q4 2021 Earnings Conference Call March 8, 2022, 8:30 am ET Company Participants Ramesh Ratan - CFO Spiros Jamas - CEO Arthur Santora - CMO Phillip Schwartz - Founder & President, R&D Conference Call Participants Kalpit Patel - B. Riley Nathan Weinstein - Aegis C...
Entera Bio press release (NASDAQ:ENTX): FY GAAP EPS of -$0.47 beats by $0.58. Revenue of $0.57M (+54.1% Y/Y) beats by $0.03M. For further details see: Entera Bio GAAP EPS of -$0.47 beats by $0.58, revenue of $0.57M beats by $0.03M
BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd . (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company’s Chief Executive Officer, Spiros Jamas, Sc.D., will present a company ov...
BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd . (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613, its oral formulation of human parathyroid hormone (1-34), or PTH, ...
News, Short Squeeze, Breakout and More Instantly...